Biohaven Ltd. (BHVN)
(Delayed Data from NYSE)
$41.47 USD
+0.28 (0.68%)
Updated May 7, 2024 04:00 PM ET
After-Market: $41.47 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BHVN 41.47 +0.28(0.68%)
Will BHVN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BHVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BHVN
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
BHVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study
Novavax (NVAX) Beats on Q3 Earnings & Sales, Cuts Sales View
Other News for BHVN
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
Biotech Sector: M&A Fuels Renewed Excitement
Fly Insider: Zura Bio, Google among week's notable insider trades
Around $1M Bet On Biohaven? Check Out These 4 Stocks Insiders Are Buying
3 Biotech Stocks to Buy on the Dip: April 2024